Key result
Baseline hs-cTnI level ≥6.5 ng/l was an independent predictor of all-cause mortality (48% vs 14%; HR 3.01, p=0.021) in patients receiving cardiac resynchronisation therapy.
Why the study?
Does baseline hs-cTnI level predict CRT response and all-cause mortality in patients with chronic heart failure receiving CRT?
Cohort (n=90)
Does baseline hs-cTnI level predict CRT response and all-cause mortality in patients with chronic heart failure receiving CRT?
Baseline hs-cTnI levels can serve as a useful prognostic biomarker for predicting CRT response and all-cause mortality in patients with chronic heart failure.
BACKGROUND: Cardiac troponin I (cTnI) is a valuable prognostic biomarker in patients with chronic heart failure (CHF). However, the prognostic importance of cTnI in patients who received cardiac resynchronisation therapy (CRT) remains unknown. The aim of this prospective study was to determine the prognostic value of high-sensitive cTnI (hs-cTnI) in CHF patients receiving CRT. METHODS: We performed measurements of baseline hs-cTnI levels in CRT patients with ischaemic as well as nonischaemic aetiology of CHF, and we investigated their possible association with response to CRT and survival of patients. RESULTS: Ninety consecutive CRT patients (mean age 64 ± 9 years, 71 men) were included. According to the best cut-off value of hs-cTnI level to predict CRT response and all cause mortality, patients were divided into group 1 (hs-cTnI level ≥6.5 ng/l, n = 46) and group 2 (hs-cTnI level <6.5 ng/l, n = 44). During the follow-up period (1155 ± 406 days), 47% of patients were CRT responders (30% in group 1 and 64% in group 2, p = .002) and 31% of patients died from any cause (48% in group 1 and 14% in group 2, p = .001). Regression analysis showed that hs-cTnI level <6.5 ng/l was an independent predictor of CRT response (OR 3.49, p = .019) and that hs-cTnI level ≥6.5 ng/l was an independent predictor of all cause mortality (HR 3.01, p = .021). CONCLUSION: The hs-cTnI can be an useful biomarker with prognostic value in patients receiving CRT.
No takes yet. Share an insight, caveat, or question.
Kerekanič et al. (2017) conducted a cohort in Chronic heart failure (n=90). Baseline hs-cTnI level ≥6.5 ng/l vs. Baseline hs-cTnI level <6.5 ng/l was evaluated on All-cause mortality (HR 3.01, p=0.021). Baseline hs-cTnI level ≥6.5 ng/l was an independent predictor of all-cause mortality (48% vs 14%; HR 3.01, p=0.021) in patients receiving cardiac resynchronisation therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: